Squamous cell carcinoma - Spinocelulární Karcinom
☆ Ve výsledcích Stiftung Warentest z Německa za rok 2022 byla spokojenost spotřebitelů s ModelDerm jen mírně nižší než s placenými telemedicínskými konzultacemi.
Squamous cell carcinoma well differentiated ― Je pozorována přilehlá aktinická keratóza.
References
Squamous cell carcinoma (SCC) je druhá nejčastější rakovina kůže ve Spojených státech po basal cell carcinoma. Obvykle začíná prekancerózními lézemi nazývanými actinic keratosis a může se rozšířit do dalších částí těla. Hlavní příčinou je vystavení ultrafialovému (UV) záření ze slunce, které se časem hromadí. Léčba obvykle zahrnuje chirurgické odstranění, zejména u SCC na hlavě a krku. Radiační terapie je možností pro starší pacienty nebo ty, kteří nemohou podstoupit operaci. Imunosuprese zvyšuje riziko SCC. Ačkoli je SCC vzácný, může se šířit, zejména u pacientů s oslabeným imunitním systémem. Pro osoby s SCC jsou důležité pravidelné kontroly a ochrana před sluncem.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) je druhou nejčastější rakovinou u lidí a její počet stoupá. Ačkoli CSCC obvykle vykazuje benigní klinické chování, může se šířit lokálně i do jiných částí těla. Vědci identifikovali specifické cesty zapojené do vývoje CSCC, které vedou k novým léčebným postupům. Vysoký počet mutací a zvýšené riziko u imunosuprimovaných pacientů podnítily rozvoj imunoterapie. Tento přehled se zabývá genetickými kořeny CSCC a nejnovějšími léčebnými postupy zaměřenými na specifické molekuly a imunitní systém.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnostika a léčba
#Dermoscopy
#Skin biopsy